Literature DB >> 15454206

Synthesis and structure-activity relationships of indole and benzimidazole piperazines as histamine H(4) receptor antagonists.

Nalan Terzioglu1, Richard M van Rijn, Remko A Bakker, Iwan J P De Esch, Rob Leurs.   

Abstract

We describe the structure-activity relationships for a series of ligands structurally related to the recently identified (5-chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone (1) as histamine H(4) receptor (H(4)R) antagonists. Furthermore, we identified related benzimidazoles as novel lead compounds for the H(4)R. The ligands have been evaluated by radioligand displacement studies and functional assays for their interaction with both the human histamine H(3) and H(4) receptors and exhibit pK(i) values up to 7.5 at the human H(4)R.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15454206     DOI: 10.1016/j.bmcl.2004.08.035

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  11 in total

Review 1.  Molecular and biochemical pharmacology of the histamine H4 receptor.

Authors:  Rob Leurs; Paul L Chazot; Fiona C Shenton; Herman D Lim; Iwan J P de Esch
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

2.  Histamine H4 receptor antagonists as potent modulators of mammalian vestibular primary neuron excitability.

Authors:  G Desmadryl; S Gaboyard-Niay; A Brugeaud; C Travo; A Broussy; A Saleur; J Dyhrfjeld-Johnsen; E Wersinger; C Chabbert
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

3.  N (α)-Methylated phenylhistamines exhibit affinity to the hH(4)R-a pharmacological and molecular modelling study.

Authors:  Hans-Joachim Wittmann; Sigurd Elz; Roland Seifert; Andrea Straber
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-07-29       Impact factor: 3.000

4.  Synthesis of 2-(N-Benzylpyrrolyl)-benzimidazoles Using Polyphosphoric Acid Prompted Cyclocondensation.

Authors:  Bereket Mochona; Laine Le; Madhavi Gangapuram; Nelly Mateeva; Tiffany Ardley; Kinfe K Redda
Journal:  J Heterocycl Chem       Date:  2010-11-01       Impact factor: 2.193

5.  Molecular modeling and QSAR studies of a set of indole and benzimidazole derivatives as H₄ receptor antagonists.

Authors:  João Paulo S Fernandes; Kerly Fernanda M Pasqualoto; Elizabeth I Ferreira; Carlos A Brandt
Journal:  J Mol Model       Date:  2010-07-06       Impact factor: 1.810

Review 6.  International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.

Authors:  Pertti Panula; Paul L Chazot; Marlon Cowart; Ralf Gutzmer; Rob Leurs; Wai L S Liu; Holger Stark; Robin L Thurmond; Helmut L Haas
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

7.  The histamine H4 receptor is functionally expressed on neurons in the mammalian CNS.

Authors:  W M Connelly; F C Shenton; N Lethbridge; R Leurs; H J Waldvogel; R L M Faull; G Lees; P L Chazot
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

8.  Pharmacological characterization of the new histamine H4 receptor agonist VUF 8430.

Authors:  Herman D Lim; Maristella Adami; Elena Guaita; Thomas Werfel; Rogier A Smits; Iwan J P de Esch; Remko A Bakker; Ralf Gutzmer; Gabriella Coruzzi; Rob Leurs
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

9.  Discovery of 8-methoxypyrazino[1,2-a]indole as a New Potent Antiproliferative Agent Against Human Leukemia K562 Cells. A Structure-Activity Relationship Study.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Maria Dora Carrion; Olga Cruz-Lopez; Carlota Lopez Cara; Delia Preti; Mojgan Aghazadeh Tabrizi; Jan Balzarini; Ernest Hamel; Enrica Fabbri; Roberto Gambari
Journal:  Lett Drug Des Discov       Date:  2009-06-01       Impact factor: 1.150

10.  2-({4-[4-(1H-Benzimidazol-2-yl)phen-yl]-1H-1,2,3-triazol-1-yl}meth-oxy)ethanol.

Authors:  Abdelaaziz Ouahrouch; Moha Taourirte; Hassan B Lazrek; Jan W Bats; Joachim W Engels
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.